Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst consensus estimate of $20.000 million by 2.96 percent. This is a 6.28 percent decrease over sales of $21.970 million the same period last year.
Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst consensus estimate of $20.000 million by 2.96 percent. This is a 6.28 percent decrease over sales of $21.970 million the same period last year.
Comments